NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke

@article{Bickerdike2009NNZ2566AG,
  title={NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke},
  author={M. J. Bickerdike and G. Thomas and D. C. Batchelor and E. Sirimanne and P. Gluckman},
  journal={Journal of the Neurological Sciences},
  year={2009},
  volume={278},
  pages={85-90}
}
The N-terminal cleavage product of human insulin-like growth factor-1 (IGF-1) in the brain is the tripeptide molecule Glypromate (Gly-Pro-Glu). Glypromate has demonstrated neuroprotective effects in numerous in vitro and in vivo models of brain injury and is in clinical trials for the prevention of cognitive impairment following cardiac surgery. NNZ-2566 is a structural analogue of Glypromate, resulting from alpha-methylation of the proline moiety, which has improved the elimination half-life… Expand
View on Elsevier
doi.org
23 Citations
Highly Influential Citations
2
Background Citations
10
Methods Citations
3
Results Citations
3

23 Citations

Citation Type

Citation Type

GPE and GPE analogues as promising neuroprotective agents.
  • 24
The role for IGF-1-derived small neuropeptides as a therapeutic target for neurological disorders
  • 20
Neuroprotection with Glycine-2-Methylproline-Glutamate (G-2MePE) after hypoxic-ischemic brain injury in adult rats
  • PDF
NNZ-2566, a Glypromate Analog, Attenuates Brain Ischemia-Induced Non-Convulsive Seizures in Rats
  • 21
  • Highly Influenced
  • PDF
Mechanism of Action for NNZ-2566 Anti-inflammatory Effects Following PBBI Involves Upregulation of Immunomodulator ATF3
  • 19
  • PDF
IGF‐1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions
  • 41
NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome
  • 41
  • PDF
Insulin‐Like Growth Factor ‐1 (IGF‐1) Derived Neuropeptides, a Novel Strategy for the Development of Pharmaceuticals for Managing Ischemic Brain Injury
  • J. Guan
  • Medicine
  • CNS neuroscience & therapeutics
  • 2011
  • 12
Population pharmacokinetics of NNZ‐2566 in healthy subjects
  • 2
  • Highly Influenced
  • PDF
Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.
  • 14
  • PDF
...
1
2
3
...

References

SHOWING 1-10 OF 36 REFERENCES
Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro.
  • 50
Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic–ischemic injury
  • 81
Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic–ischemic adult rats
  • 63
Delayed Peripheral Administration of a GPE Analogue Induces Astrogliosis and Angiogenesis and Reduces Inflammation and Brain Injury following Hypoxia-Ischemia in the Neonatal Rat
  • 35
Pharmacokinetics of glycine-proline-glutamate, the N-terminal tripeptide of insulin-like growth factor-1, in rats.
  • 32
Central penetration and stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat
  • 41
Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide.
  • 94
N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats
  • 89
Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats.
  • 66
Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain.
  • 36
...
1
2
3
4
...